According to data presented by Dr. Philip A. Salem at the ASCO Breakthrough Conference in Singapore, a personalized therapeutic strategy combining chemotherapy, immunotherapy, and targeted treatment yielded an overall remission rate of 87.6% in 73 evaluable patients with advanced, terminal, or refractory malignancies. The approach, termed ICTriplex, tailors multimodality regimens to the specific genomic and biological profile of each individual tumor rather than applying a fixed combination uniformly.
Clinical Outcomes and Remission Rates in Advanced Malignancies
The single-center study, conducted at the Salem Oncology Center in Houston between March 2017 and February 2026, evaluated 73 patients with advanced cancers who had exhausted standard therapies or lacked optimal treatment options. Dr. Salem reported that the overall remission rate reached 87.6%, which included a complete remission rate of 47.9% and a partial remission rate of 39.7%. Complete remissions were documented across nearly all treated tumor types, with the exception of ovarian cancer and sarcoma.
Lung cancer emerged as the most sensitive malignancy in the cohort, showing a complete remission rate of 64%. Among five lung cancer patients presenting with brain metastases, four achieved complete remission in the brain simultaneously with systemic complete remission, while one patient achieved systemic complete remission without clearing the intracranial disease. Four patients who entered the program with terminal diagnoses remain alive and disease-free at the five-year mark, according to the data.
Did You Know? Complete remissions achieved through the ICTriplex strategy were significantly associated with extended survival outcomes, yielding a median progression-free survival of 15 months and a median overall survival of 41 months in the study population.
Personalized Biology-Driven Treatment Design
ICTriplex functions as a personalized therapeutic framework rather than a rigid drug protocol. Every patient in the Houston cohort received a custom regimen built on three concurrent modalities: standard chemotherapy agents such as taxanes, gemcitabine, and platinum compounds; immune checkpoint inhibitors including atezolizumab, nivolumab, and pembrolizumab; and targeted therapies such as bevacizumab and erlotinib. Treatment design relied heavily on exhaustive genomic and biological profiling of the patient’s tumor.
The study population encompassed a diverse array of advanced diagnoses, including 14 lung cancer cases, 13 colorectal cases, 11 pancreatic cases, 6 biliary tract cases, 6 breast cases, 4 ovarian cases, 4 sarcomas, 3 glioblastoma multiformes, 3 melanomas, 3 gastric cases, 2 cervical cases, and 4 other tumor types. Dr. Salem and colleagues noted that because genomic profiling demonstrates that every cancer is biologically unique, matching the three therapeutic modalities to individual tumor biology accounts for differences in patients who share identical anatomic diagnoses.
Future Directions for Refractory Cancer Therapy
Following the presentation at the ASCO Breakthrough Conference, researchers emphasize that continued clinical study of ICTriplex is warranted to better define its role in oncology. The findings extend previously published data from the Salem Oncology Center regarding multimodality approaches in heavily pretreated populations. Investigators suggest that ICTriplex should be considered a viable clinical option for patients facing advanced or refractory malignancies who have no remaining standard treatment options.
Frequently Asked Questions
What is ICTriplex?
ICTriplex is a personalized therapeutic strategy that simultaneously combines chemotherapy, immune checkpoint inhibitors, and targeted therapy, with each patient’s specific regimen tailored to their tumor’s genomic profile.
What were the results of the Salem Oncology Center study?
According to data presented by Dr. Philip A. Salem, the study of 73 evaluable patients with advanced or refractory cancer showed an overall remission rate of 87.6%, including a 47.9% complete remission rate and a 39.7% partial remission rate.
Which cancer types showed the highest sensitivity?
Lung cancer demonstrated the highest sensitivity in the cohort, achieving a complete remission rate of 64%.
What are your thoughts on personalized multimodality cancer treatments? Share your perspective in the comments below, or explore our archive for more coverage on oncology research.